Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients—an evidence-based approach

[1]  P. Verweij,et al.  Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model. , 2014, The Journal of antimicrobial chemotherapy.

[2]  A. McLachlan,et al.  Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. , 2014, The Journal of antimicrobial chemotherapy.

[3]  Steven W. Johnson,et al.  Recent advances in the treatment of life-threatening, invasive fungal infections , 2013, Expert opinion on pharmacotherapy.

[4]  H. Itoh,et al.  Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[5]  S. Seyedmousavi,et al.  Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis , 2013, Expert review of anti-infective therapy.

[6]  D. Buchheidt,et al.  Invasive aspergillosis: new insights into disease, diagnostic and treatment. , 2013, Current pharmaceutical design.

[7]  Y. Nishi,et al.  Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring , 2013, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[8]  D. Jayne,et al.  SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .

[9]  M. Hoenigl,et al.  Potential Factors for Inadequate Voriconazole Plasma Concentrations in Intensive Care Unit Patients and Patients with Hematological Malignancies , 2013, Antimicrobial Agents and Chemotherapy.

[10]  D. Andes.  Optimizing antifungal choice and administration , 2013, Current medical research and opinion.

[11]  D. Fredricks,et al.  Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events , 2013, BMC Infectious Diseases.

[12]  H. Koo,et al.  Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis , 2013, Pediatric blood & cancer.

[13]  M. Kainer,et al.  Fungal infections associated with contaminated methylprednisolone in Tennessee. , 2012, The New England journal of medicine.

[14]  J. Nagel,et al.  Evaluation of the effect of obesity on voriconazole serum concentrations. , 2012, The Journal of antimicrobial chemotherapy.

[15]  G. Würthwein,et al.  Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients. , 2012, The Journal of antimicrobial chemotherapy.

[16]  M. Kouba,et al.  Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience , 2012, Mycoses.

[17]  T. Egberts,et al.  Highly Variable Plasma Concentrations of Voriconazole in Pediatric Hematopoietic Stem Cell Transplantation Patients , 2012, Antimicrobial Agents and Chemotherapy.

[18]  P. G. Choe,et al.  The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  T. Buclin,et al.  Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  A. McLachlan,et al.  Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring , 2012, Antimicrobial Agents and Chemotherapy.

[21]  S. Klein,et al.  A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepine , 2012, British journal of clinical pharmacology.

[22]  P. Soler-Palacín,et al.  Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study. , 2012, The Journal of antimicrobial chemotherapy.

[23]  J. Pilewski,et al.  Prospective, Observational Study of Voriconazole Therapeutic Drug Monitoring among Lung Transplant Recipients Receiving Prophylaxis: Factors Impacting Levels of and Associations between Serum Troughs, Efficacy, and Toxicity , 2012, Antimicrobial Agents and Chemotherapy.

[24]  Joo-Youn Cho,et al.  Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers , 2012, Journal of clinical pharmacology.

[25]  W. Hope.  Population Pharmacokinetics of Voriconazole in Adults , 2011, Antimicrobial Agents and Chemotherapy.

[26]  D. Yim,et al.  Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients. , 2011, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[27]  P. Troke,et al.  Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients , 2011, Antimicrobial Agents and Chemotherapy.

[28]  A. Thiébaut,et al.  European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update , 2011, Bone Marrow Transplantation.

[29]  N. Venisse,et al.  Niveau de preuve du suivi thérapeutique pharmacologique du voriconazole. , 2011 .

[30]  W. Haefeli,et al.  Modulators of Very Low Voriconazole Concentrations in Routine Therapeutic Drug Monitoring , 2011, Therapeutic drug monitoring.

[31]  G. Meyfroidt,et al.  Voriconazole plasma levels in children are highly variable , 2011, European Journal of Clinical Microbiology & Infectious Diseases.

[32]  S. Eymard-Duvernay,et al.  Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring , 2010, Xenobiotica; the fate of foreign compounds in biological systems.

[33]  J. Mehta,et al.  Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: preemptive dose modification and therapeutic drug monitoring , 2010, Bone Marrow Transplantation.

[34]  D. Niederwieser,et al.  Voriconazole Pharmacokinetics and Safety in Immunocompromised Children Compared to Adult Patients , 2010, Antimicrobial Agents and Chemotherapy.

[35]  S. Markantonis,et al.  Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study. , 2010, International journal of antimicrobial agents.

[36]  P. Chandrasekar,et al.  Safety of triazole antifungal drugs in patients with cancer. , 2010, The Journal of antimicrobial chemotherapy.

[37]  M. Kurokawa,et al.  Monitoring Trough Concentration of Voriconazole Is Important to Ensure Successful Antifungal Therapy and to Avoid Hepatic Damage in Patients with Hematological Disorders. , 2009 .

[38]  J. Mehta,et al.  Serial Plasma Voriconazole Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation , 2009, Antimicrobial Agents and Chemotherapy.

[39]  Zeruesenay Desta,et al.  Comprehensive In Vitro Analysis of Voriconazole Inhibition of Eight Cytochrome P450 (CYP) Enzymes: Major Effect on CYPs 2B6, 2C9, 2C19, and 3A , 2008, Antimicrobial Agents and Chemotherapy.

[40]  D. Touw,et al.  International Interlaboratory Proficiency Testing Program for Measurement of Azole Antifungal Plasma Concentrations , 2008, Antimicrobial Agents and Chemotherapy.

[41]  D. Denning,et al.  Voriconazole plasma monitoring , 2008, Archives of Disease in Childhood.

[42]  Raoul Herbrecht,et al.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  Thierry Buclin,et al.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  L. Gordon,et al.  Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole , 2007, Bone Marrow Transplantation.

[45]  D. Hillaire‐buys,et al.  Adverse Effects of Voriconazole: Analysis of the French Pharmacovigilance Database , 2007, The Annals of pharmacotherapy.

[46]  L. Gordon,et al.  Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients , 2007, Cancer.

[47]  D. Schaer,et al.  Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. , 2006, Swiss medical weekly.

[48]  D. Andes,et al.  Voriconazole Therapeutic Drug Monitoring , 2006, Antimicrobial Agents and Chemotherapy.

[49]  J. Mehta,et al.  Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients , 2005, Bone Marrow Transplantation.

[50]  D. Andes,et al.  In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.

[51]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[52]  N. Wood,et al.  Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens , 2002, Antimicrobial Agents and Chemotherapy.

[53]  H. Lazarus,et al.  Safety and Pharmacokinetics of Oral Voriconazole in Patients at Risk of Fungal Infection: A Dose Escalation Study , 2002, Journal of clinical pharmacology.

[54]  E. Thiel,et al.  Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[55]  M A Kish,et al.  Guide to development of practice guidelines. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[56]  M. Rinaldi,et al.  Comparison of High-Performance Liquid Chromatographic and Microbiological Methods for Determination of Voriconazole Levels in Plasma , 2000, Antimicrobial Agents and Chemotherapy.

[57]  J. Balian,et al.  Determination of CYP2C19 phenotype in black Americans with omeprazole: Correlation with genotype , 1996, Clinical pharmacology and therapeutics.

[58]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.

[59]  F. Lemaitre,et al.  A case-report of unpredictable and massive voriconazole intoxication in a patient with extensive CYP2C19 and CYP2C9 polymorphisms. , 2013, Drug metabolism and pharmacokinetics.

[60]  Yoshiro Saito,et al.  Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. , 2012, Drug metabolism and pharmacokinetics.

[61]  A. Hulin,et al.  [Level of evidence for therapeutic drug monitoring of voriconazole]. , 2011, Therapie.

[62]  A. McLachlan,et al.  Clinical importance of the CYP2C19*17 variant allele for voriconazole. , 2011, British journal of clinical pharmacology.

[63]  R. Jelliffe,et al.  Voriconazole pharmacokinetics and pharmacodynamics in children. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[64]  H. Derendorf,et al.  Pharmacokinetic/Pharmacodynamic Profile of Posaconazole , 2010, Clinical pharmacokinetics.

[65]  H. Derendorf,et al.  Pharmacokinetic/Pharmacodynamic Profile of Voriconazole , 2006, Clinical pharmacokinetics.

[66]  M. Karthaus.  Voriconazole versus amphotericin B for invasive aspergillosis. , 2002, The New England journal of medicine.